Your browser doesn't support javascript.
loading
Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need.
Hirsch, G; Trusheim, M; Cobbs, E; Bala, M; Garner, S; Hartman, D; Isaacs, K; Lumpkin, M; Lim, R; Oye, K; Pezalla, E; Saltonstall, P; Selker, H.
Afiliação
  • Hirsch G; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Trusheim M; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Cobbs E; Merck, Kenilworth, New Jersey, USA.
  • Bala M; Sanofi, Seattle, Washington, USA.
  • Garner S; National Institute for Health and Clinical Excellence (NICE), London, UK.
  • Hartman D; Bill and Melinda Gates Foundation, Seattle, Washington, USA.
  • Isaacs K; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Lumpkin M; Bill and Melinda Gates Foundation, Seattle, Washington, USA.
  • Lim R; Health Canada, Ottawa, Ontario, Canada.
  • Oye K; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Pezalla E; Aetna, Hartford, Connecticut, USA.
  • Saltonstall P; National Organization for Rare Disorders (NORD), Danbury, Connecticut, USA.
  • Selker H; Tufts University, Boston, Massachusetts, USA.
Clin Pharmacol Ther ; 100(6): 685-698, 2016 12.
Article em En | MEDLINE | ID: mdl-27626610
ABSTRACT
The current system of biomedical innovation is unable to keep pace with scientific advancements. We propose to address this gap by reengineering innovation processes to accelerate reliable delivery of products that address unmet medical needs. Adaptive biomedical innovation (ABI) provides an integrative, strategic approach for process innovation. Although the term "ABI" is new, it encompasses fragmented "tools" that have been developed across the global pharmaceutical industry, and could accelerate the evolution of the system through more coordinated application. ABI involves bringing stakeholders together to set shared objectives, foster trust, structure decision-making, and manage expectations through rapid-cycle feedback loops that maximize product knowledge and reduce uncertainty in a continuous, adaptive, and sustainable learning healthcare system. Adaptive decision-making, a core element of ABI, provides a framework for structuring decision-making designed to manage two types of uncertainty - the maturity of scientific and clinical knowledge, and the behaviors of other critical stakeholders.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tomada de Decisões / Atenção à Saúde / Pesquisa Biomédica / Difusão de Inovações / Indústria Farmacêutica Tipo de estudo: Prognostic_studies / Sysrev_observational_studies Aspecto: Determinantes_sociais_saude Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tomada de Decisões / Atenção à Saúde / Pesquisa Biomédica / Difusão de Inovações / Indústria Farmacêutica Tipo de estudo: Prognostic_studies / Sysrev_observational_studies Aspecto: Determinantes_sociais_saude Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos